Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Dynavax Technologies Corporation (NASDAQ: DVAX) increased by over 9% pre-market. This is why it happened.

DVAX Stock Price Increases Over 9% Pre-Market: Why It Happened

The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.

Dynavax's Q4 Results Show It's Not Just About Heplisav-B Anymore

Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q4 2020 Results - Earnings Call Transcript

EMERYVILLE, Calif., Feb. 25, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the fourth quarter and full year 2020. "2020 was an important year...

Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results

Is (DVAX) Outperforming Other Medical Stocks This Year?

Has Dynavax Technologies (DVAX) Outpaced Other Medical Stocks This Year?

EMERYVILLE, Calif., Feb. 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that the European Commission (EC) has granted Marketing Authorization for HEPLISAV B...

Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Dynavax Technologies (DVAX) closed the most recent trading day at $9.82, moving +0.41% from the previous trading session.

Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know

EMERYVILLE, Calif., Feb. 16, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the Cowen 41st Annual Health Care...

Dynavax to Present at the Cowen 41st Annual Health Care Conference

Dynavax Technologies (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Dynavax (DVAX)

EMERYVILLE, Calif., Feb. 8, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Dong Yu, Ph.D., has joined the Company as Senior Vice President of Vaccine Research and a...

Dong Yu, Ph.D., Joins Dynavax as Senior Vice President of Vaccine Research

Coherus BioSciences

Exelixis

Illumina

I-Mab

Eli Lilly

Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1

Dynavax Technologies Corporation (NASDAQ: DVAX) and Serum Institute of India (SII) have dosed the first patient in Phase 1 clinical trial evaluating tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccine candidate, adjuvanted with CpG 1018.

Dynavax, Serum Institute Start Phase 1 Trial For Tdap Booster Vaccine

The stock price of Dynavax Technologies Corporation (NASDAQ: DVAX) increased by 62.76% today. This is why it happened.

DVAX Stock Price Increased 62.76%: Why It Happened

Why Dynavax Stock Is Skyrocketing Today

Dynavax Technologies Corporation (NASDAQ: DVAX) shares are advancing solidly after the company and Clover Biopharma issued an update on their joint coronavirus vaccine program. What Happened: China-based Clover and Dynavax said they plan to initiate a global Phase 2/3 study efficacy trial with the former's S-Trimer COVID-19 vaccine, adjuvanted with the latter's CpG 1018, plus alum, in the first half of 2021.

Why Dynavax Shares Are Rallying Today

EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced Valneva SE has informed it that the UK Government exercised its option to order an...

Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government

OSLO, Norway AND EMERYVILLE, Calif., Feb. 1, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced they have...

Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. The Coalition for...

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Clovis Oncology

Lannett Company

Cenntro Electric Group

OPKO Health

Precigen

Senseonics Holdings

TherapeuticsMD

United Microelectronics

VBI Vaccines

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's known as a short squeeze.

10 Short Squeeze Candidates Under $10

Lexinfintech Hlds

One is making a COVID-19 vaccine; the other is a fintech.

2 Great Stocks Under $10 a Share

TAIPEI, TAIWAN and EMERYVILLE, Calif., Jan. 25, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO) a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation (Nasdaq: DVAX), a...

Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

EMERYVILLE, Calif., Jan. 20, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Kelly MacDonald has been appointed Senior Vice President and Chief Financial Officer. Ms....

Dynavax Appoints Kelly MacDonald as Chief Financial Officer

The company reported positive clinical results for its hepatitis B vaccine.

Why Dynavax Stock Is Vaulting Higher Today

EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual...

News for Dynavax Technologies Stock (DVAX)